A higher proportion of patients with previous TNF antagonist failure given vedolizumab also had a CDAI-@ response ( @-point decrease in CDAI score from baseline ) at week @ than those given placebo ( @ % vs @ % ; nominal P = @ ; relative risk , @ ; @ % confidence interval , @-@ @ ) .